Prognostic and predictive markers of benefit from adjuvant chemotherapy in early-stage non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 4, Issue 7, 2009, Pages 891-910

  Custodio, Ana Belén ^b   González Larriba, José Luis ^a   Bobokova, Jana ^a   Calles, Antonio ^a   Álvarez, Rafael ^a   Cuadrado, Eugenio ^a   Manzano, Aranzazu ^a   Díaz Rubio, Eduardo ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b s/n Ciudad Universitaria ^*  (Spain)

Author keywords

Early stages; Molecular prognostic and predictive markers; Non small cell lung cancer; Platinumbased adjuvant chemotherapy

Indexed keywords

BETA TUBULIN; BRCA1 PROTEIN; CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; MOLECULAR MARKER; NAVELBINE; PACLITAXEL; PROTEIN P53; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE SUBUNIT M1; UNCLASSIFIED DRUG; VINCA ALKALOID; VINCRISTINE;

CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CELL CYCLE REGULATION; DNA METHYLATION; DNA REPAIR; GENE EXPRESSION PROFILING; GENE SILENCING; HUMAN; LUNG NON SMALL CELL CANCER; MORTALITY; ONCOGENE K RAS; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RELAPSE; REVIEW; RISK FACTOR; SURVIVAL TIME;

EID: 68549127070     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181a4b8fb     Document Type: Review

References (144)

1. Jernal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-130.
2. Ponn RB, Lo Cicero J III, Daly BDT. Surgical treatment of non small cell lung cancer. In Shields TW, Lo Cicero J III, Ponn R, Rusch VW (Eds.). General Thoracic Surgery, 6th Ed. Philadelphia: Lippincott Williams & Wilkins, 2005. Pp. 1548-1587.
3. Wright G, Manser RL, Byrnes G, Hart D, Campbell DA. Surgery for early-stage non-small cell lung cancer: systematic review and metaanalysis of randomised controlled trials. Thorax 2006;61:597-603. (Pubitemid 44035140)
4. Strauss GM. Adjuvant chemotherapy of lung cancer: methodologic issues and therapeutic advances. Hematol Oncol Clin North Am 2005; 19:263-281. (Pubitemid 40502853)
5. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med 2004;350:351-360. (Pubitemid 38101630)
6. Douillard JY, Rosell R, de Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006;7:719-727. (Pubitemid 44283661)
7. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus Cisplatin vs. Observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-2597. (Pubitemid 41007845)
8. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung Adjuvant Cisplatin Evaluation (LACE): a pooled analysis of 5 randomized trials including 4584 patients. J Clin Oncol 2006;24:366S. [Abstract No. 7008 2006 ASCO Annual Meeting.]
9. Strauss GM, Herndon JE, Maddaus MA, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) Protocol 9633. J Clin Oncol 2004;22:7019.
10. Strauss GM, Herndon JE, Maddaus MA, et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of cancer and Leukemia Group B (CALGB) protocol 9633. J Clin Oncol 2008;26: 5043-5051. [Abstract No. 7007 2006 ASCO Annual Meeting.]
11. Nesbitt JC, Putnam JB Jr, Walsh GL, Roth JA, Mountain CF. Survival in early-stage non-small cell lung cancer. Ann Thorac Surg 1995;60: 466-472.
12. Hoang T, Xu R, Schiller JH, Bonomi P, Johnson DH. Clinical model to predict survival in chemonaïve patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol 2005;23: 175-183. (Pubitemid 41702636)
13. Forrest LM, McMillan DC, McArdle CS, Angerson WT, Dagg K, Scott HR. A prospective longitudinal study of performance status, an inflammation- based score (GPS) and survival in patients with inoperable non-small-cell lung cancer. Br J Cancer 2005;92:1834-1836. (Pubitemid 40826128)
14. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in nonsmall cell lung cancer: a decade of progress. Chest 2002;122:1037-1057.
15. Meyerson M, Carbone DP. Genomic and proteomic profiling of lung cancers: lung cancer classification in the age of targeted therapy. J Clin Oncol 2005;23:3219-3226. (Pubitemid 46211346)
16. Endoh H, Tomida S, Yatabe Y, et al. Prognostic model of pulmonary adenocarcinoma by expression profiling of eight genes as determined by quantitative real-time reverse transcriptase polymerase chain reaction. J Clin Oncol 2004;22:811-819. (Pubitemid 41103592)
17. Wigle DA, Jurisica I, Radulovich N, et al. Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. Cancer Res 2002;62:3005-3008. (Pubitemid 34602385)
18. Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002;8:816-824.
19. Schneider PM, Praeuer HW, Stoeltzing O, et al. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer. Br J Cancer 2000;83:473-479. (Pubitemid 30487860)
20. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995;270:467-470.
21. Hoheisel JD. Microarray technology: beyond transcript profiling and genotype analysis. Nat Rev Genet 2006;7:200-210.
22. Ramaswamy S. Tranlating cancer genomics into clinical oncology. N Engl J Med 2004;350:1814-1816. (Pubitemid 38917246)
23. Garber ME, Troyanskaya OG, Schluens K, et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A 2001;98:13784 -13789. (Erratum Proc Natl Acad Sci U S A 2002;99: 1098.) (Pubitemid 33115976)
24. Chen JJ, Peck K, Hong TM, et al. Global analysis of gene expression in invasion by a lung cancer model. Cancer Res 2001;61:5223-5230. (Pubitemid 32681557)
25. Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006;355:570-580. (Pubitemid 44200650)
26. Chen HY, Yu SL, Chen CH, et al. A five-gene signature and clinical outcome in non-small cell lung cancer. N Engl J Med 2007;356:11-20. (Pubitemid 46041749)
27. Yu H, Jove R. The STATs of cancer-new molecular targets come on age. Nat Rev Cancer 2004;4:97-105. (Pubitemid 38198738)
28. Kumar A, Commane M, Flickinger TW, Horvath CM, Stark GR. Defective TNF-alpha-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases. Science 1997;278:1630-1632. (Pubitemid 27516283)
29. Rehli M, Krause SW, Schwarzfischer L, Kreutz M, Andreesen R. Molecular cloning of a novel macrophage maturation-associated transcript encoding a protein with several potential transmembrane domains. Biochem Biophys Res Commun 1995;217:661-667. (Pubitemid 26011760)
30. Chen JJ, Lin YC, Yao PL, et al. Tumor-associated macrophages: the double-edged sword in cancer progression. J Clin Oncol 2005;23:953-964. (Pubitemid 46202315)
31. Furukawa T, Sunamura M, Motoi F, Matsuno S, Horii A. Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. Am J Pathol 2003;162:1807-1815. (Pubitemid 36613039)
32. Muller-Tidow C, Diederichs S, Bulk E, et al. Identification of metastasis- associated receptor tyrosine kinases in non-small cell lung cancer. Cancer Res 2005;65:1778-1782. (Pubitemid 40478604)
33. Zamoyska R, Basson A, Filby A, Legname G, Lovatt M, Seddon B. The influence of the src-family kinases, on T cell differentiation, survival and activation. Immunol Rev 2003;191:107-118. (Pubitemid 36398852)
34. Mahabeleshwar GH, Das R, Kundu GC. Tyrosine Kinase, p56lckinduced cell motility, and urokinase-type plasminogen activator secretion involve activation of epidermal growth factor receptor/extracellular regulated kinase pathways. J Biol Chem 2004;279:9733-9742. (Pubitemid 38372571)
35. Mahabeleshwar GH, Kundu GC. Tyrosine Kinase p56lck regulates cell motility and nuclear factor kappa B-mediated secretion of urokinase type plasminogen activator through tyrosine phosphorylation of IkappaBalpha following hipoxia/reoxygenation. J Biol Chem 2003;278: 52598-52612.
36. Skrzypski M, Jassem E, Mendez P, et al. Expression profile of 29 genes by real-time quantitative PCR (RT-QPCR) in early-stage (I-IIIA) squamous cell carcinoma of the lung (SCCL). J Clin Oncol 2007; 25(supp):abstract 7612.
37. Skrzypski M, Jassem E, Benlloch S, et al. Validation of 5- and 3-gene expression signatures for predicting outcome in non-small cell lung cancer (NSCLC) patients (p). J Clin Oncol 2008;26(supp):abstract 7532.
38. Tsao MS, Zhu C, Ding K, et al. A 15-gene expression signature prognostic for survival and predictive for adjuvant chemotherapy benefit in JBR. 10 patients. J Clin Oncol 2008;26(supp):abstract 7510.
39. Le Chevalier T, Dunant A, Arriagada R, et al. Long-term results of the Internacional Adjuvant Lung Cancer Trial (IALT) evaluating adjuvant cisplatin-based chemotherapy in resected non-small cell lung cancer (NSCLC). J Clin Oncol 2008;26(supp):abstract 7507.
40. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355:983-991. (Pubitemid 44343542)
41. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 1998;24:331-344. (Pubitemid 28537769)
42. Zamble DB, Mu D, Reardon JT, Sancar A, Lippard SJ. Repair of cisplatin-DNA adducts by the mammalian excision nuclease. Biochemistry 1996;35:10004-10013. (Pubitemid 26269915)
43. De Silva IU, McHugh PJ, Clingen PH, Hartley JA. Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol Cell Biol 2000;20: 7980-7990. (Pubitemid 30777715)
44. Niedernhofer LJ, Odijk H, Budzowska M, et al. The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand crosslink- induced double-strand breaks. Mol Cell Biol 2004;24:5776-5787. (Pubitemid 38787963)
45. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002;8: 2286-2291. (Pubitemid 34753602)
46. Altaha R, Liang X, Yu JJ, Reed E. Escisión repair cross complementing- group 1: gene expresion and platinum resistance. Int J Mol Med 2004;14:959-970.
47. Joshi MB, Shirota Y, Danenberg KD, et al. High gene expresión of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 2005;11:2215-2221. (Pubitemid 40500464)
48. Zhou W, Gurubhagavatula S, Liu G, et al. Excision repair crosscomplementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinumbased chemotherapy. Clin Cancer Res 2004;10:4939-4943. (Pubitemid 39099767)
49. Viguier J, Boige V, Miquel C, et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluoruracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 2005;11:6212-6217. (Pubitemid 41262950)
50. Simon GR, Sharma S, Cantor A, Smith P, Bepler G. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 2005;127:978-983. (Pubitemid 40775532)
51. Bepler G, Gautam A, McIntyre LM, et al. Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small-cell lung cnacer. J Clin Oncol 2002;20:1353-1360. (Pubitemid 34177442)
52. Gautam A, Li ZR, Bepler G. RRM1-induced metastasis suppresion through PTEN-regulated pathways. Oncogene 2003;22:2135-2142. (Pubitemid 36539563)
53. Fan H, Huang A, Villegas C, Wright JA. The R1 component of mammalian ribonucleotide reductase has malignancy-supressing activity as demonstrated by gene transfer experiments. Proc Natl Acad Sci U S A 1997;94:13181-13186. (Pubitemid 27518496)
54. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-1947. (Pubitemid 27148818)
55. Gautam A, Bepler G. Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase. Cancer Res 2006;66: 6497-6502. (Pubitemid 44085603)
56. Bepler G, Sharma S, Cantor A, et al. RRM1 and PTEN as prognostic parameter for overall and disease-free survival in patients with nonsmall- cell lung cancer. J Clin Oncol 2004;22:1878-1885. (Pubitemid 41095179)
57. Gridelli C, Gallo C, Shepherd FA, et al. Gemcitabine plus vinorelbine compared with cisplatin with vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003;21:3025-3034. (Pubitemid 46606281)
58. Treat J, Belani C, Edelman M, et al. A randomized phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in advanced non-small cell lung cancer: update of the Alpha Oncology trial (A1-99002L). Proc Am Soc Clin Oncol 2005;23:627s. Abstract.
59. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007;356:800-808. (Pubitemid 46294612)
60. Bertheau P, Cazals-Hatem D, Meignin V, et al. Variability of immunohistochemical reactivity on stored paraffin slides. J Clin Pathol 1998;51:370-374. (Pubitemid 28289123)
61. McCabe A, Dolled-Filhart M, Camp RL, Rimm DL. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst 2005;97:1808-1815. (Pubitemid 43033901)
62. Kennedy RD, Quinn JE, Johnston PG, Harkin DP. BRCA1: mechanisms of inactivation and implications for management of patients. Lancet 2002;360:1007-1014.
63. Mullan PB, Quinn JE, Gilmore PR, et al. BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene 2001;20:6123-6131.
64. Lotti LV, Ottini L, D'Amico C, et al. Subcellular localization of the BRCA1 gene product in mitotic cells. Genes Chromosomes Cancer 2002;35:193-203.
65. Harkin DP, Bean JM, Miklos D, et al. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell 1999;97:575-586. (Pubitemid 29256961)
66. Potapova O, Haghighi A, Bost F, et al. The Jun Kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin. J Biol Chem 1997; 272:14041-14044. (Pubitemid 27232804)
67. Lafarge S, Sylvain V, Ferrara M, Bignon YJ. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene 2001;20:6597-6606. (Pubitemid 32980286)
68. Taron M, Rosell R, Felip E, et al. BRCA1 mRNA expresión levels as an indicador of chemoresistance in lung cancer. Human Molecular Genetics 2004;13:2443-2449. (Pubitemid 39377848)
69. Rosell R, Jassem E, Skrzypski M, et al. Increased BRCA1 mRNA: an independent prognostic variable in completely resected chemo-naïve non-small cell lung cancer (NSCLC) patienst (p). J Clin Oncol 2007; 25(supp):abstract 7551.
70. Rosell R, Skrzypski M, Jassem E, et al. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PloS ONE 2007;2:e1129. (Pubitemid 351594028)
71. Hromas R, Collins SJ, Hickstein D, et al. A retinoic acid-responsive human zinc finger gene, MZF-1, preferentially expressed in myeloid cells. J Biol Chem 1991;266:14183-14187. (Pubitemid 21907481)
72. Yan QW, Reed E, Zhong XS, Thornton K, Guo Y, Yu JJ. MZF1possesses a repressively regulatory function in ERCC1 expression. Biochem Pharmacol 2006;71:761-771. (Pubitemid 43208832)
73. Le Mee S, Fromigue O, Marie PJ. Sp1/Sp3 and the myeloid zinc finger gene MZF1 regulate the human N-cadherin promoter in osteoblasts. Exp Cell Res 2005;302:129-142. (Pubitemid 39482374)
74. Yang J, Mani SA, Donaher JL, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004; 117:927-939. (Pubitemid 38798858)
75. Alexander NR, Tran NL, Rekapally H, Summers CE, Glackin C, Heimark RL. N-cadherin gene expression in prostate carcinoma is modulated by integrin-dependent nuclear translocation of Twist1. Cancer Res 2006;66:3365-3369.
76. Kakolyris S, Giatromanolaki A, Koukourakis M, et al. Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer. Clin Cancer Res 2001;7:3087-3091. (Pubitemid 32963828)
77. Yoshida T, Nakamura H, Masutani H, Yodoi J. The involvement of thioredoxin and thioredoxin binding protein-2 on cellular proliferation and aging process. Ann N Y Acad Sci 2005;1055:1-12. (Pubitemid 43211660)
78. Rosell R, Scagliotti G, Danenberg KD, et al. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic nonsmall- cell lung cancer. Oncogene 2003;22:3548-3553. (Pubitemid 36765314)
79. Rosell R, Felip E, Taron M, et al. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res 2004;10:4215s- 4219s. (Pubitemid 38812449)
80. Interthal H, Chen HJ, Kehl-Fie TE, Zotzmann J, Leppard JB, Champoux JJ. SCAN1 mutant Tdp1 accumulates the enzyme-DNA intermediate and causes camptothecin hypersensitivity. Embo J 2005;24: 2224-2233. (Pubitemid 40961806)
81. Barthelmes HU, Habermeyer M, Christensen MO, et al. TDP1 overexpression in human cells counteracts DNA damage mediated by topoisomerases I and II. J Biol Chem 2004;279:55618-55625. (Pubitemid 40066566)
82. Liu C, Zhou S, Begum S, et al. Increased expression and activity of repair genes TDP1 and XPF in non-small cell lung cancer. Lung Cancer 2007;55:303-311. (Pubitemid 46329184)
83. Yoeli-Lerner M, Yiu GK, Rabinovitz I, Erhardt P, Jauliac S, Toker A. Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. Mol Cell 2005;20:539-550. (Pubitemid 41668639)
84. Jauliac S, Lopez-Rodriguez C, Shaw LM, Brown LF, Rao A, Toker A. The role of NFAT transcription factors in integrin-mediated carcinoma invasion. Nat Cell Biol 2002;4:540-544. (Pubitemid 34752442)
85. Bae I, Rih JK, Kim HJ, et al. BRCA1 regulates gene expression for orderly mitotic progression. Cell Cycle 2005;4:1641-1666. (Pubitemid 41609148)
86. Chabalier C, Lamare C, Racca C, Privat M, Valette A, Larminat F. 2BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle 2006;5:1001-1007.
87. Shichiri M, Yoshinaga K, Hisatomi H, Sugihara K, Hirata Y. Genetic and epigenetic inactivation of mitotic checkpoint genes hBUB1 and hBUBR1 and their relationship to survival. Cancer Res 2002;62:13-17. (Pubitemid 34073977)
88. Quinn J, Kennedy RD, Mullan PB, et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003;63:6221-6228. (Pubitemid 37255167)
89. Quinn J, James C, Stewart G, et al. BRCA1 mRNA expression levels predict for overall survival on ovarian cancer after chemotherapy. Clin Cancer Res 2007;13:7413-7420.
90. Cobo M, Massuti T, Morán T, et al. Spanish customized adjuvant trial (SCAT) based on BRCA1 mRNA levels. J Clin Oncol 2008;26(supp): abstract 7533.
91. Bartolucci R, Botia M, Mendez P, et al. Influence of XPG mRNA levels on the effect of BRCA1 mRNA levels in pronosis of early non-small cell lung cancer (NSCLC). J Clin Oncol 2008;26(supp): abstract 7545.
92. Burkhart CA, Kavallaris M; Horwitz SB. The role of β-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta 2001;1471: 1-9. (Pubitemid 32146550)
93. Kavallaris M, Kuo DY, Burkhart CA, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 1997;100:1282-1293. (Pubitemid 27386315)
94. Ranganathan S, Benetatos CA, Colarusso PJ, Dexter DW, Hudes GR. Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer 1998;77:562-566. (Pubitemid 28059462)
95. Liu B, Staren ED, Iwamura T, Appert HE, Howard JM. Mechanisms of taxotere-related drug resistance in pancreatic carcinoma. J Surg Res 2001;99:179-186. (Pubitemid 32703435)
96. Kavallaris M, Tait AS, Walsh BJ, et al. Multiple microtubule alterations are associated with vinca alkaloid resistance in human leukemia cells. Cancer Res 2001;61:5803-5809. (Pubitemid 32769098)
97. Dumuntet C, Jaffrezou JP, Tsuchiya E, et al. Resistance to microtubuletargeted cytotoxins in a K562 leukemia cell variant associated with altered tubulin expression and polymerization. Bull Cancer 2004;91: E81-E112.
98. Giannakakou P, Sackett DL, Kang YK, et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997;272: 17118-17125. (Pubitemid 27289821)
99. Lu Q, Luduena RF. Removal of beta III isotype enhances taxol induced microtubule assembly. Cell Struct Funct 1993;18:173-182. (Pubitemid 23307472)
100. Banerjee A, Roach MC, Trcka P, Luduena RF. Increased microtubule assembly in bovine brain tubulin lacking the type III isotype of beta-tubulin. J Biol Chem 1990;265:1794-1799. (Pubitemid 20049015)
101. Sève P, Isaac S, Tredan O, et al. Expresión of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 2005;11:5481-5486. (Pubitemid 41060824)
102. Dumontet C, Isaac S, Souquet PJ, et al. Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bull Cancer 2005;92:E25-E30.
103. Séve P, Mackey J, Isaac S, et al. Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 2005;4:2001-2007. (Pubitemid 43056983)
104. Séve P, Lai R, Ding K, et al. Class III β-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable nonsmall cell lung cancer: analysis of NCIC JBR. 10. Clin Cancer Res 2007;13:994-999. (Pubitemid 46340378)
105. Aschele C, Debernardis D, Casazza S, et al. Immunohistochemical quantitation of thymidylate synthase expresión in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol 1999;17:1760-1770. (Pubitemid 29269245)
106. Edler D, Glimelius B, Hallstrom M, et al. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluoro-uracil-based chemotherapy. J Clin Oncol 2002;20:1721-1728. (Pubitemid 34273259)
107. Reiman T, Seve P, Vataire A, et al. Prognostic value of class III b-tubulin (TUBB3) in operable non-small cell lung cancer (NSCLC) and predictive value for adjuvant cisplatin-based chemotherapy (CT): a validation study on three randomized trials. J Clin Oncol 2008; 26(supp):abstract 7506.
108. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene 2005;24:2899-2908.
109. Aviel-Ronen S, Blackhall FH, Shepherd FA, Tsao MS. K-ras mutations in non-small-cell lung carcinoma: a review. Clin Lung Cancer 2006; 8:30-38. (Pubitemid 44336241)
110. Mitsudomi T, Hamajima N, Ogawa M, Takahashi T. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 2000;6:4055-4063. (Pubitemid 30807100)
111. Mascaux C, Iannino N, Martin B, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2005;92:131-139. (Pubitemid 40188446)
112. Steels E, Paesmans M, Berghmans T, et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 2001;18:705-719. (Pubitemid 33040631)
113. Huncharek M, Muscat J, Geschwind JF. K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. Carcinogenesis 1999;20:1507-1510. (Pubitemid 29385437)
114. Kyzas PA, Loizou KT, Ioannidis JP. Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst 2005;97:1043-1055.
115. Zhu CQ, Shih W, Ling CH, Tsao MS. Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for amultiphase approach to marker evaluation. J Clin Pathol 2006;59:790-800. (Pubitemid 44211740)
116. McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97:1180-1184. (Pubitemid 41258223)
117. Sengupta S, Harris CC. p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol 2005;6:44-55. (Pubitemid 40064898)
118. Tsao M, Aviel-Ronen S, Ding K, et al. Prognostic and Predictive Importante of p53 and RAS for adjuvant chemotherapy in non-smallcell lung cancer. J Clin Oncol 2007;25:5240-5247. (Pubitemid 350232256)
119. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC Tp53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002;19:607-614. (Pubitemid 34556481)
120. Hall PA, Lane DP. p53 in tumour pathology: can we trust immunohistochemistry?- revisited! J Pathol 1994;172:1-4.
121. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-4878. (Pubitemid 24289415)
122. Deb SP. Cell cycle regulatory functions of the human oncoprotein MDM2. Mol Cancer Res 2003;1:1009-1016.
123. Midgley CA, Lane DP. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 1997;15:1179-1189.
124. Wang YC, Lin RK, Tan YH, Chen JT, Chen CY, Wang YC. Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer. J Clin Oncol 2005;23:154-164.
125. Brown JM, Wouters BG. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 1999;59:1391-1399.
126. Lowe SW, Sherr CJ. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr Opin Gen Dev 2003;13:77-83.
127. Fan S, Chang JK, Smith ML, Duba D, Fornace AJ Jr, O'Connor PM. Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard. Oncogene 1997;14:2127-2136. (Pubitemid 27248224)
128. Filipits M, Pirker R, Dunant A, et al. Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected nonsmall- cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program. J Clin Oncol 2007;25:2735-2740. (Pubitemid 47123181)
129. Rekhtman N, Azzoli CG, Kris MG, et al. Patterns of co-expression of ERCC1 and p27 in resected non-small cell lung cancer by immunohistochemistry. J Clin Oncol 2008;26(supp):abstract 7595.
130. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-2054. (Pubitemid 37448928)
131. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer- a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006;6:107-116.
132. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001;61:3225-3229. (Pubitemid 32695003)
133. Brock M, Hooker C, Ota-Machida E, et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 2008;358: 1118-1128.
134. Belinsky SA, Nikula KJ, Palmisano WA, et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A 1998;95:11891-11896. (Pubitemid 28460510)
135. Toyooka KO, Toyooka S, Virmani AK, et al. Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res 2001;61:4556-4560. (Pubitemid 32685789)
136. Toyooka S, Toyooka KO, Maruyama R, et al. DNA methylation profiles of lung tumors. Mol Cancer Ther 2001;1:61-67.
137. Machida EO, Brock MV, Hooker CM, et al. Hypermethylation of ASC/TMS1 is a sputum marker for late-stage lung cancer. Cancer Res 2006;66:6210-6218.
138. Brock MV, Kim MP, Hooker CM, et al. Pulmonary resection in octogenarians with stage I nonsmall cell lung cancer: a 22-year experience. Ann Thorac Surg 2004;77:271-277.
139. Pellisé M, Castells A, Ginès A, et al. Detection of lymph node micrometastases by gene promoter hypermethylation in samples obtained by endosonography-guided fine-needle aspiration biopsy. Clin Cancer Res 2004;10:4444-4449. (Pubitemid 38878887)
140. Harden SV, Tokumaru Y, Westra WH, et al. Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clin Cancer Res 2003;9:1370-1375. (Pubitemid 36418388)
141. Gu J, Berman D, Lu C, et al. Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer. Clin Cancer Res 2006;12:7329-7338. (Pubitemid 46095405)
142. Wang J, Lee JJ, Wang L, et al. Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung
143. Safar AM, Spencer H, Su X, Cooney CA, Shwaiki A, Fan CY. Promoter hypermethylation for molecular nodal staging in non-small cell lung cancer. Arch Pathol Lab Med 2007;131:936-941. (Pubitemid 46906386)
144. Belinsky SA, Liechty KC, Gentry FD, et al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res 2006;66:3338-3344.